DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
BMS-817399
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
C-C chemokine receptor type 1 antagonist
BMS-817399
×
Maximum Phase:
2
First Approval:
None
UNII:
AKQ3X6FEH0
Molecule Type:
Small molecule
Molecular Formula:
C23H36ClN3O4
Molecular Weight:
454.01
AlogP:
2.88
PSA:
101.9
HBD:
4.0
HBA:
#RotB:
6.0
Source:
ELZASONAN
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major
Unknown
ELZASONAN
×
Maximum Phase:
2
First Approval:
None
UNII:
933PJL964R
Molecule Type:
Small molecule
Molecular Formula:
C22H23Cl2N3OS
Molecular Weight:
448.42
AlogP:
4.87
PSA:
26.79
HBD:
0.0
HBA:
#RotB:
3.0
Source:
VAPENDAVIR
2
Small molecule
Investigational
Unknown
Unknown
Asthma
VP1 capsid protein inhibitor
VAPENDAVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
Q8LVL5Z68H
Molecule Type:
Small molecule
Molecular Formula:
C21H26N4O3
Molecular Weight:
382.46
AlogP:
4.01
PSA:
73.51
HBD:
0.0
HBA:
#RotB:
7.0
Source:
ROZIBAFUSP ALFA
2
Protein
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lupus Erythematosus, Systemic
Unknown
ROZIBAFUSP ALFA
×
Maximum Phase:
2
First Approval:
None
UNII:
O9YF5SN7KL
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LCB01-0371
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LCB01-0371
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IVA337
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
IVA337
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TALAMPANEL
2
Small molecule
Investigational
Unknown
Unknown
Amyotrophic Lateral Sclerosis; Astrocytoma; Central Nervous System Neoplasms; Epilepsy; Glioblastoma; Oligodendroglioma; Parkinson Disease
Glutamate receptor ionotropic, AMPA 1 antagonist
TALAMPANEL
×
Maximum Phase:
2
First Approval:
None
UNII:
CVS43XG1L5
Molecule Type:
Small molecule
Molecular Formula:
C19H19N3O3
Molecular Weight:
337.38
AlogP:
2.54
PSA:
77.15
HBD:
1.0
HBA:
#RotB:
1.0
Source:
CHROMIUM NICOTINATE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
CHROMIUM NICOTINATE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VIDOFLUDIMUS
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Cholangitis, Sclerosing; Colitis, Ulcerative; Inflammatory Bowel Diseases; Multiple Sclerosis; Severe Acute Respiratory Syndrome
Dihydroorotate dehydrogenase inhibitor
VIDOFLUDIMUS
×
Maximum Phase:
2
First Approval:
None
UNII:
8Y1PJ3VG81
Molecule Type:
Small molecule
Molecular Formula:
C20H18FNO4
Molecular Weight:
355.37
AlogP:
4.0
PSA:
75.63
HBD:
2.0
HBA:
#RotB:
5.0
Source:
18F-DTBZ
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
18F-DTBZ
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMARADENANT
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Prostatic Neoplasms, Castration-Resistant
Adenosine A2a receptor antagonist
IMARADENANT
×
Maximum Phase:
2
First Approval:
None
UNII:
770140J08A
Molecule Type:
Small molecule
Molecular Formula:
C15H11ClFN5
Molecular Weight:
315.74
AlogP:
3.28
PSA:
77.58
HBD:
1.0
HBA:
#RotB:
2.0
Source:
ALFLUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung
Epidermal growth factor receptor erbB1 inhibitor
ALFLUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
A49A7A5YN4
Molecule Type:
Small molecule
Molecular Formula:
C28H31F3N8O2
Molecular Weight:
568.6
AlogP:
4.84
PSA:
100.44
HBD:
2.0
HBA:
#RotB:
11.0
Source:
TEBANICLINE TOSYLATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Neuronal acetylcholine receptor; alpha4/beta2 agonist
TEBANICLINE TOSYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
CP1A26546Z
Molecule Type:
Small molecule
Molecular Formula:
C16H19ClN2O4S
Molecular Weight:
370.86
AlogP:
1.48
PSA:
34.15
HBD:
1.0
HBA:
#RotB:
3.0
Source:
SELONSERTIB
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Hepatitis, Alcoholic; Hypertension, Pulmonary
Mitogen-activated protein kinase kinase kinase 5 inhibitor
SELONSERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
NS3988A2TC
Molecule Type:
Small molecule
Molecular Formula:
C24H24FN7O
Molecular Weight:
445.5
AlogP:
4.68
PSA:
90.52
HBD:
1.0
HBA:
#RotB:
6.0
Source:
PALTUSOTINE
2
Unknown
Investigational
Unknown
Unknown
Acromegaly
Unknown
PALTUSOTINE
×
Maximum Phase:
2
First Approval:
None
UNII:
F2IBD1GMD3
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PHORBOL MYRISTATE ACETATE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Leukemia
Unknown
PHORBOL MYRISTATE ACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
NI40JAQ945
Molecule Type:
Small molecule
Molecular Formula:
C36H56O8
Molecular Weight:
616.84
AlogP:
5.75
PSA:
130.36
HBD:
3.0
HBA:
#RotB:
15.0
Source:
ONO-2952
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome
Translocator protein antagonist
ONO-2952
×
Maximum Phase:
2
First Approval:
None
UNII:
ZH8CPX4YNB
Molecule Type:
Small molecule
Molecular Formula:
C22H20ClFN2O2
Molecular Weight:
398.87
AlogP:
4.95
PSA:
45.33
HBD:
1.0
HBA:
#RotB:
2.0
Source:
EMVODODSTAT
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Leukemia, Myeloid, Acute; Neoplasms; Neurofibromatosis 2
Unknown
EMVODODSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C25H20Cl2N2O3
Molecular Weight:
467.35
AlogP:
6.63
PSA:
54.56
HBD:
1.0
HBA:
#RotB:
3.0
Source:
DENENICOKIN
2
Protein
Investigational
Unknown
Unknown
Carcinoma, Renal Cell; Lymphoma, Non-Hodgkin; Neoplasms; Melanoma
Unknown
DENENICOKIN
×
Maximum Phase:
2
First Approval:
None
UNII:
A4LY1V9F0H
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CYTIDINE
2
Small molecule
Investigational
Unknown
Unknown
Bipolar Disorder
Unknown
CYTIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
5CSZ8459RP
Molecule Type:
Small molecule
Molecular Formula:
C9H13N3O5
Molecular Weight:
243.22
AlogP:
-2.56
PSA:
130.83
HBD:
4.0
HBA:
#RotB:
2.0
Source:
BERUBICIN HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma; Glioblastoma; Glioma
DNA topoisomerase II inhibitor
BERUBICIN HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
7BA3X03948
Molecule Type:
Small molecule
Molecular Formula:
C34H36ClNO11
Molecular Weight:
670.11
AlogP:
2.23
PSA:
195.07
HBD:
5.0
HBA:
#RotB:
8.0
Source:
HEME ARGINATE
2
Small molecule
Investigational
Unknown
Unknown
Myocardial Infarction; Acute Kidney Injury; Myocardial Ischemia; Porphyrias; Reperfusion Injury
Unknown
HEME ARGINATE
×
Maximum Phase:
2
First Approval:
None
UNII:
R1B526117P
Molecule Type:
Small molecule
Molecular Formula:
C40H48FeN8O6+2
Molecular Weight:
792.72
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
RADEZOLID
2
Small molecule
Investigational
Unknown
Unknown
Pneumonia
Bacterial 70S ribosome inhibitor
RADEZOLID
×
Maximum Phase:
2
First Approval:
None
UNII:
53PC6LO35W
Molecule Type:
Small molecule
Molecular Formula:
C22H23FN6O3
Molecular Weight:
438.46
AlogP:
2.36
PSA:
112.24
HBD:
3.0
HBA:
#RotB:
8.0
Source:
GPI-1485
2
Small molecule
Investigational
Unknown
Unknown
Parkinson Disease
Unknown
GPI-1485
×
Maximum Phase:
2
First Approval:
None
UNII:
0709BVY57W
Molecule Type:
Small molecule
Molecular Formula:
C12H19NO4
Molecular Weight:
241.29
AlogP:
1.07
PSA:
74.68
HBD:
1.0
HBA:
#RotB:
4.0
Source:
IBOGAINE
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Opioid-Related Disorders
Unknown
IBOGAINE
×
Maximum Phase:
2
First Approval:
None
UNII:
3S814I130U
Molecule Type:
Small molecule
Molecular Formula:
C20H26N2O
Molecular Weight:
310.44
AlogP:
3.94
PSA:
28.26
HBD:
1.0
HBA:
#RotB:
2.0
Source:
TETRAHYDROURIDINE
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Anemia, Sickle Cell; Central Nervous System Neoplasms; Head and Neck Neoplasms; Myelodysplastic Syndromes; Neoplasms; Carcinoma, Non-Small-Cell Lung
Unknown
TETRAHYDROURIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
0NIZ8H6OL8
Molecule Type:
Small molecule
Molecular Formula:
C9H16N2O6
Molecular Weight:
248.24
AlogP:
-2.84
PSA:
122.49
HBD:
5.0
HBA:
#RotB:
2.0
Source:
LONCASTUXIMAB TESIRINE
2
Antibody
Investigational
Unknown
Unknown
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse
B-lymphocyte antigen CD19 binding agent
LONCASTUXIMAB TESIRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
7K5O7P6QIU
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AZD4205
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Lymphoma, T-Cell, Peripheral
Tyrosine-protein kinase JAK1 inhibitor
AZD4205
×
Maximum Phase:
2
First Approval:
None
UNII:
3BY9Z3M34G
Molecule Type:
Small molecule
Molecular Formula:
C25H31N9O2
Molecular Weight:
489.58
AlogP:
2.69
PSA:
116.23
HBD:
3.0
HBA:
#RotB:
7.0
Source:
ODELEPRAN
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism
Opioid receptors; mu/kappa/delta antagonist
ODELEPRAN
×
Maximum Phase:
2
First Approval:
None
UNII:
4VZT670SD9
Molecule Type:
Small molecule
Molecular Formula:
C20H24FN3O3
Molecular Weight:
373.43
AlogP:
3.02
PSA:
86.47
HBD:
2.0
HBA:
#RotB:
8.0
Source:
VERPASEP CALTESPEN
2
Protein
Investigational
Unknown
Unknown
Anus Neoplasms; Cervical Intraepithelial Neoplasia; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms
Unknown
VERPASEP CALTESPEN
×
Maximum Phase:
2
First Approval:
None
UNII:
Z7T0JI2E2I
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NARONAPRIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Serotonin 4 (5-HT4) receptor agonist
NARONAPRIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
058896B00B
Molecule Type:
Small molecule
Molecular Formula:
C27H41ClN4O5
Molecular Weight:
537.1
AlogP:
2.95
PSA:
106.36
HBD:
2.0
HBA:
#RotB:
11.0
Source:
PF-04531083
2
Small molecule
Investigational
Unknown
Unknown
Chronic Pain; Toothache
Sodium channel protein type X alpha subunit blocker
PF-04531083
×
Maximum Phase:
2
First Approval:
None
UNII:
40497CY7Y3
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELSIGLUTIDE
2
Protein
Investigational
Unknown
Unknown
Diarrhea
Glucagon-like peptide 2 receptor agonist
ELSIGLUTIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
SC864Q40VB
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELOCALCITOL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Vitamin D receptor agonist
ELOCALCITOL
×
Maximum Phase:
2
First Approval:
None
UNII:
2WDS5F2V6Q
Molecule Type:
Small molecule
Molecular Formula:
C29H44O3
Molecular Weight:
440.67
AlogP:
6.18
PSA:
60.69
HBD:
3.0
HBA:
#RotB:
7.0
Source:
FIRATEGRAST
2
Small molecule
Investigational
Unknown
Unknown
Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis
Integrin alpha-4/beta-1 antagonist
FIRATEGRAST
×
Maximum Phase:
2
First Approval:
None
UNII:
OJY3SK9H5F
Molecule Type:
Small molecule
Molecular Formula:
C27H27F2NO6
Molecular Weight:
499.51
AlogP:
4.61
PSA:
94.09
HBD:
2.0
HBA:
#RotB:
11.0
Source:
1
2
…
183
184
185
186
187
188
189
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA